Correlation Between Zentalis Pharmaceuticals and Viridian Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Zentalis Pharmaceuticals and Viridian Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Zentalis Pharmaceuticals and Viridian Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Zentalis Pharmaceuticals Llc and Viridian Therapeutics, you can compare the effects of market volatilities on Zentalis Pharmaceuticals and Viridian Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Zentalis Pharmaceuticals with a short position of Viridian Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Zentalis Pharmaceuticals and Viridian Therapeutics.

Diversification Opportunities for Zentalis Pharmaceuticals and Viridian Therapeutics

-0.02
  Correlation Coefficient

Good diversification

The 3 months correlation between Zentalis and Viridian is -0.02. Overlapping area represents the amount of risk that can be diversified away by holding Zentalis Pharmaceuticals Llc and Viridian Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Viridian Therapeutics and Zentalis Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Zentalis Pharmaceuticals Llc are associated (or correlated) with Viridian Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Viridian Therapeutics has no effect on the direction of Zentalis Pharmaceuticals i.e., Zentalis Pharmaceuticals and Viridian Therapeutics go up and down completely randomly.

Pair Corralation between Zentalis Pharmaceuticals and Viridian Therapeutics

Given the investment horizon of 90 days Zentalis Pharmaceuticals Llc is expected to generate 1.76 times more return on investment than Viridian Therapeutics. However, Zentalis Pharmaceuticals is 1.76 times more volatile than Viridian Therapeutics. It trades about -0.02 of its potential returns per unit of risk. Viridian Therapeutics is currently generating about -0.07 per unit of risk. If you would invest  368.00  in Zentalis Pharmaceuticals Llc on September 16, 2024 and sell it today you would lose (59.00) from holding Zentalis Pharmaceuticals Llc or give up 16.03% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Zentalis Pharmaceuticals Llc  vs.  Viridian Therapeutics

 Performance 
       Timeline  
Zentalis Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Zentalis Pharmaceuticals Llc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain persistent and the latest mess on Wall Street may also be a sign of long-standing gains for the company institutional investors.
Viridian Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Viridian Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's fundamental indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Zentalis Pharmaceuticals and Viridian Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Zentalis Pharmaceuticals and Viridian Therapeutics

The main advantage of trading using opposite Zentalis Pharmaceuticals and Viridian Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Zentalis Pharmaceuticals position performs unexpectedly, Viridian Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viridian Therapeutics will offset losses from the drop in Viridian Therapeutics' long position.
The idea behind Zentalis Pharmaceuticals Llc and Viridian Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Other Complementary Tools

Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Stocks Directory
Find actively traded stocks across global markets
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges